Transforming Hospitalizations of Autistic Adolescents via a Novel ABA Telehealth Platform
Caring Technologies, Inc., Boise ID
Investigators
Abstract
You said: Phase II TABA Research Strategy 1R44MH134706.pdf PDF based on the attached plan, what is a good 'Project Summary/Abstract' in the convenÆonal terminology and length typically done for a Phase II AdministraÆve Supplement for TABA? ChatGPT said: ChatGPT Hereâs a convenÆonal "Project Summary/Abstract" based on the attached Phase II TABA plan: Project Summary/Abstract We are requesÆng Phase II Technical and Business Assistance (TABA) funding to advance the commercializaÆon of Hospital TeleABA, an innovaÆve telehealth platiorm designed to support hospital care for auÆsÆc children and adolescents. This funding will enable the strategic implementaÆon of our soluÆon into hospital systems, with plans for future expansion into schools and residenÆal settings for auÆsÆc teens and adults. Our Phase I research demonstrated the feasibility and potenÆal of Hospital TeleABA to enhance behavioral support for hospitalized adolescents with auÆsm. Over 109 I-Corps interviews and more than 120 stakeholder feedback sessions validated the need for our telehealth soluÆon, confirming its uÆlity in improving behavior management and discharge planning. The prototype we developed successfully integrated trauma-informed behavior stabilizaÆon (TIBS) protocols, and preliminary trials demonstrated strong clinical uÆlity, with a 97% correlaÆon in behavior idenÆficaÆon between remote observers and in- person evaluaÆons. To ensure successful commercializaÆon, we will leverage TABA funding to access strategic guidance in markeÆng, regulatory compliance, and reimbursement pracÆces. This will be facilitated through partnerships with the Council of AuÆsm Service Providers (CASP) and DRA CollecÆve, Inc., who will provide criÆcal experÆse in operaÆonal guidelines, billing pracÆces, and strategic market posiÆoning. Our goal is to establish Hospital TeleABA as the leading telehealth platiorm for behavioral support in hospital settings, while building the capacity to scale naÆonwide. With TABA support, we aim to solidify our market presence ahead of clinical trials set to begin in early 2025, ensuring that our soluÆon meets the high standards of care expected in hospitals, while also aligning with the best pracÆces established by CASP.
View original record on NIH RePORTER →